Case report: Squamous cell carcinoma and spindle cell sarcoma (SCS) arising in a mature cystic teratoma of the ovary.

Objective: Malignant transformation of mature ovarian teratoma is a rare phenomenon, mainly occurring in postmenopausal period. Squamous cell carcinoma accounts for 80% of all malignant transformations. Sarcoma transformation is much less common and tends to imply a poorer prognosis and aggressiveness.

Extra-abdominal metastases from epithelial ovarian carcinoma: an analysis of 20 cases.

Objective: To investigate the clinicopathologic risk factors associated with extra-abdominal metastases in epithelial ovarian carcinoma patients and to determine prognostic factors associated with survival.

Methods: A retrospective chart review was conducted on 20 cases of epithelial ovarian carcinoma patients with extra-abdominal metastases and 645 cases of epithelial ovarian carcinoma patients without extra-abdominal metastases treated at our unit between 1993 and 2007.

Results: A total of 25 extra-abdominal metastatic sites were diagnosed in 20 patients.

Methotrexate induces apoptosis of human choriocarcinoma cell line JAR via a mitochondrial pathway.

Objective: To investigate methotrexate (MTX)-induced apoptosis and the involved pathways in human choriocarcinoma cells.

Study Design: MTX-induced apoptosis of human choriocarcinoma cell line JAR was examined using a PI/Annexin V stain with flow cytometer (FCM). Mitochondrial apoptosis was detected by fluorescence microscopy, and analyzed by FCM using a MitoCapture mitochondrial apoptosis detection kit.

[Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].

Objective: To evaluate the effects of primary chemotherapy with single-agent methotrexate (MTX) on low-risk gestational trophoblastic neoplasia (GTN) and the influencing factors thereof.

Methods: Sixty-one GTN patients with the score of < or = 6 according to the new International Federation of Gynecology and Obstetrics (FIGO) scoring system (2000) were divided into 2 groups: 51 patients were treated with single MTX 0.4 mg/kg daily for 5 days (MTX 5 d group), and 10 patients were treated with MTX on the days 1, 3, 5, and 7, and with folinic acid (FA) 0.

[cDNA microarray analysis of gene expression in acquired methotrexate-resistant of human choriocarcinoma].

Objective: To identify the molecular components involved in acquired methotrexate-resistance of human choriocarcinoma.

Methods: Methotrexate-resistant cell line (JAR/MTX) was derived from JAR cell line by exposed to intervally and progressively increasing higher concentration of MTX. cDNA microarray analyses of JAR/MTX and its parental cell line JAR were performed.

[Establishment of methotrexate-resistant human choriocarcinoma cell line and its biological characteristics].

Objective: To establish a methotrexate (MTX)-resistant choriocarcinoma cell line and to determine its biologic characteristics.

Methods: MTX-resistant cell line (JAR/MTX) was derived from human choriocarcinoma cell line JAR by exposed to intermittently and progressively increasing concentration of MTX. Drug sensitivity was detected by MTT; P-gp GST-Pi and PCNA expressions were detected by immunohistochemistry.

[Efficacy and side effects of methotrexate in the treatment of ectopic pregnancy].

Objective: To study the efficacy and side effects of methotrexate with different protocols in the treatment of ectopic pregnancy (EP).

Methods: Total of 648 patients who had EP and were treated only with MTX were analysed. Patients were divided into six groups according to protocol: Group 1, 100 mg intravenously (IV); Group 2, 100 mg, IV, followed by citrovorum factor; Group 3, 20 mg, IV every day for five days; Group 4, 20 mg intramusculary (IM) every day for five days; Group 5, 75 mg, IV; Group 6, 75 mg, IM.